1. Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses.
- Author
-
Xu J, Yang D, Huang D, Xu J, Liu S, Lin H, Zhu H, Liu B, and Lu C
- Subjects
- Animals, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Cell Line, Cytokines biosynthesis, Cytokines immunology, Dogs, Guinea Pigs, Hemagglutinin Glycoproteins, Influenza Virus biosynthesis, Hemagglutinin Glycoproteins, Influenza Virus genetics, Influenza A Virus, H1N1 Subtype genetics, Influenza A Virus, H3N2 Subtype genetics, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections prevention & control, Orthomyxoviridae Infections virology, Suipoxvirus immunology, Swine, Swine Diseases immunology, Swine Diseases prevention & control, Th1 Cells immunology, Th2 Cells immunology, Vaccination veterinary, Vaccines, Synthetic immunology, Hemagglutinin Glycoproteins, Influenza Virus immunology, Influenza A Virus, H1N1 Subtype immunology, Influenza A Virus, H3N2 Subtype immunology, Influenza Vaccines immunology, Orthomyxoviridae Infections veterinary, Suipoxvirus genetics
- Abstract
Swine influenza (SI) is an acute respiratory infectious disease of swine caused by swine influenza virus (SIV). SIV is not only an important respiratory pathogen in pigs but also a potent threat to human health. Here, we report the construction of a recombinant swinepox virus (rSPV/H3-2A-H1) co-expressing hemagglutinin (HA1) of SIV subtypes H1N1 and H3N2. Immune responses and protection efficacy of the rSPV/H3-2A-H1 were evaluated in guinea pigs. Inoculation of rSPV/H3-2A-H1 yielded neutralizing antibodies against SIV H1N1 and H3N2. The IFN-γ and IL-4 concentrations in the supernatant of lymphocytes stimulated with purified SIV HA1 antigen were significantly higher (P < 0.01) than those of the control groups. Complete protection of guinea pigs against SIV H1N1 or H3N2 challenge was observed. No SIV shedding was detected from guinea pigs vaccinated with rSPV/H3-2A-H1 after challenge. Most importantly, the guinea pigs immunized with rSPV/H3-2A-H1 did not show gross and micrographic lung lesions. However, the control guinea pigs experienced distinct gross and micrographic lung lesions at 7 days post-challenge. Our data suggest that the recombinant swinepox virus encoding HA1 of SIV H1N1 and H3N2 might serve as a promising candidate vaccine for protection against SIV H1N1 and H3N2 infections.
- Published
- 2013
- Full Text
- View/download PDF